NCT07036796RecruitingPhase 2
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Effect of Melatonin on the Clinical Outcomes in Type 2 Diabetic Patients With Peripheral Neuropathy
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 4 Jul 2025
- Primary completion date
- 4 Jul 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07036796
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 4 Jul 2025 to the primary completion date, 4 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications or supplements known to cause or treat peripheral neuropathy.
- Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment.
Other illness
- Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.
- Patients diagnosed with neurodegenerative diseases.
- Active infection.
- Allergy to melatonin.
Other
- Patients with severe kidney or liver dysfunction.
- Alcohol consumption or substance abuse.
- Pregnancy or lactation or expecting to get pregnant during the study.
Who the study is looking for
- Patients aged 40-75 years diagnosed with type 2 DM.
- Diabetes duration at least 1 year.
- Patients diagnosed with diabetic peripheral neuropathy.
- Stable antidiabetic medication for at least 1 month before enrollment and during the trial
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.